Company profile KTTA

Pasithea Therapeutics Corp
Description of the company is not available.
Quarter analysis & expected interestLast update: February 07 2024 23:46:04.

After 38 days of this quarter the interest is at 69.0. Based on that we can calculate that during remaining 53 days it will total up to 165.0.
Pasithea Therapeutics expected interest is significantly higher compared to previous quarter (+302.4%) and same quarter last year (+266.7%).

YearQ1Q2Q3Q4
20190
0
0
0
2020 0
0
0
43
inf% YoY inf% QoQ
2021 21
inf% YoY -51.2% QoQ
100
inf% YoY 376.2% QoQ
147
inf% YoY 47.0% QoQ
373
767.4% YoY 153.7% QoQ
2022 208
890.5% YoY -44.2% QoQ
100
0.0% YoY -51.9% QoQ
246
67.3% YoY 146.0% QoQ
160
-57.1% YoY -35.0% QoQ
2023 45
-78.4% YoY -71.9% QoQ
63
-37.0% YoY 40.0% QoQ
0
-100.0% YoY -100.0% QoQ
41
-74.4% YoY inf% QoQ
2024 69
53.3% YoY 68.3% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Pasithea Therapeutics search interestLast update: February 07 2024 23:46:03.
Correlation coefficient between keyword and revenue is 0.9
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 23:46:04.

The average 5 years interest of Pasithea Therapeutics was 6.22 per week.
The last year interest of Pasithea Therapeutics compared to the last 5 years has changed by -37.78%.
This is something to be checked.
This didn't exist 5 years ago.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 07 2024 23:46:08.

After 38 days of this quarter the interest is at 80.0. Based on that we can calculate that during remaining 53 days it will total up to 192.0.
Pasithea Therapeutics Corp expected interest is significantly higher compared to previous quarter (+92.0%) and same quarter last year (+255.6%).

YearQ1Q2Q3Q4
201934
28
-17.6% QoQ
48
71.4% QoQ
170
254.2% QoQ
2020 39
14.7% YoY -77.1% QoQ
100
257.1% YoY 156.4% QoQ
105
118.8% YoY 5.0% QoQ
138
-18.8% YoY 31.4% QoQ
2021 153
292.3% YoY 10.9% QoQ
177
77.0% YoY 15.7% QoQ
33
-68.6% YoY -81.4% QoQ
55
-60.1% YoY 66.7% QoQ
2022 159
3.9% YoY 189.1% QoQ
127
-28.2% YoY -20.1% QoQ
239
624.2% YoY 88.2% QoQ
75
36.4% YoY -68.6% QoQ
2023 54
-66.0% YoY -28.0% QoQ
68
-46.5% YoY 25.9% QoQ
24
-90.0% YoY -64.7% QoQ
100
33.3% YoY 316.7% QoQ
2024 80
48.1% YoY -20.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Pasithea Therapeutics Corp search interestLast update: February 07 2024 23:46:08.
Correlation coefficient between keyword and revenue is 0.58
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 23:46:09.

The average 5 years interest of Pasithea Therapeutics Corp was 7.72 per week.
The last year interest of Pasithea Therapeutics Corp compared to the last 5 years has changed by -23.58%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 2.25%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 07 2024 23:46:13.

After 38 days of this quarter the interest is at 61.0. Based on that we can calculate that during remaining 53 days it will total up to 146.0.
Pasithea Therapeutics stock expected interest is significantly higher compared to same quarter last year (+87.2%) but similar to previous quarter.

YearQ1Q2Q3Q4
2019163
102
-37.4% QoQ
45
-55.9% QoQ
24
-46.7% QoQ
2020 52
-68.1% YoY 116.7% QoQ
39
-61.8% YoY -25.0% QoQ
53
17.8% YoY 35.9% QoQ
101
320.8% YoY 90.6% QoQ
2021 88
69.2% YoY -12.9% QoQ
90
130.8% YoY 2.3% QoQ
63
18.9% YoY -30.0% QoQ
122
20.8% YoY 93.7% QoQ
2022 37
-58.0% YoY -69.7% QoQ
44
-51.1% YoY 18.9% QoQ
0
-100.0% YoY -100.0% QoQ
35
-71.3% YoY inf% QoQ
2023 78
110.8% YoY 122.9% QoQ
59
34.1% YoY -24.4% QoQ
87
inf% YoY 47.5% QoQ
162
362.9% YoY 86.2% QoQ
2024 61
-21.8% YoY -62.3% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Pasithea Therapeutics stock search interestLast update: February 07 2024 23:46:13.
Correlation coefficient between keyword and revenue is -0.84
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 23:46:14.

The average 5 years interest of Pasithea Therapeutics stock was 5.79 per week.
The last year interest of Pasithea Therapeutics stock compared to the last 5 years has changed by 41.45%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 20.26%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pasithea Therapeutics treatment to provide analysis

Correlation between past revenue and Pasithea Therapeutics treatment search interest

There is not enough data for Pasithea Therapeutics treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pasithea Therapeutics treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pasithea Therapeutics RASopathies to provide analysis

Correlation between past revenue and Pasithea Therapeutics RASopathies search interest

There is not enough data for Pasithea Therapeutics RASopathies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pasithea Therapeutics RASopathies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pasithea Therapeutics CNS disorders to provide analysis

Correlation between past revenue and Pasithea Therapeutics CNS disorders search interest

There is not enough data for Pasithea Therapeutics CNS disorders to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pasithea Therapeutics CNS disorders to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pasithea Therapeutics biotechnology to provide analysis

Correlation between past revenue and Pasithea Therapeutics biotechnology search interest

There is not enough data for Pasithea Therapeutics biotechnology to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pasithea Therapeutics biotechnology to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pasithea Therapeutics clinics to provide analysis

Correlation between past revenue and Pasithea Therapeutics clinics search interest

There is not enough data for Pasithea Therapeutics clinics to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pasithea Therapeutics clinics to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pasithea Therapeutics PAS-004 to provide analysis

Correlation between past revenue and Pasithea Therapeutics PAS-004 search interest

There is not enough data for Pasithea Therapeutics PAS-004 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pasithea Therapeutics PAS-004 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pasithea Therapeutics amyotrophic lateral sclerosis to provide analysis

Correlation between past revenue and Pasithea Therapeutics amyotrophic lateral sclerosis search interest

There is not enough data for Pasithea Therapeutics amyotrophic lateral sclerosis to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pasithea Therapeutics amyotrophic lateral sclerosis to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for KTTA
Earnings date: 2024-03-30 After close
Company name: Pasithea Therapeutics Corp
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-04T11:01:00Z

GlobeNewswire
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

2026-04-20T16:27:39Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price Target

2026-04-20T11:01:00Z

GlobeNewswire
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

2026-04-01T11:01:00Z

GlobeNewswire
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

2026-02-17T12:01:00Z

GlobeNewswire
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-13T12:01:00Z

GlobeNewswire
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

2025-12-08T12:44:13Z

Analyst Upgrades
HC Wainwright & Co. Initiates Coverage On Pasithea Therapeutics with Buy Rating, Announces Price Target of $3

2025-12-02T12:00:00Z

GlobeNewswire
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

2025-11-28T14:20:00Z

GlobeNewswire
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

2025-11-25T12:00:00Z

GlobeNewswire
Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS

2025-11-24T12:00:00Z

GlobeNewswire
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

2025-11-21T17:35:00Z

GlobeNewswire
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

2025-11-20T21:01:00Z

GlobeNewswire
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

2025-11-04T12:03:00Z

GlobeNewswire
Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

2025-09-16T07:04:47-04:00

SEC
8-K Form - Current report, items 7.01, 8.01, and 9.01 - Pasithea Therapeutics Corp. (0001841330) (Filer)